PL3527210T3 - Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania - Google Patents
Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowaniaInfo
- Publication number
- PL3527210T3 PL3527210T3 PL17881171T PL17881171T PL3527210T3 PL 3527210 T3 PL3527210 T3 PL 3527210T3 PL 17881171 T PL17881171 T PL 17881171T PL 17881171 T PL17881171 T PL 17881171T PL 3527210 T3 PL3527210 T3 PL 3527210T3
- Authority
- PL
- Poland
- Prior art keywords
- androgen receptor
- receptor pathway
- combined composition
- pathway modulator
- benzoheterocyclic compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611170723 | 2016-12-16 | ||
| EP17881171.7A EP3527210B1 (en) | 2016-12-16 | 2017-12-15 | Combined composition comprising a benzoheterocyclic compound and an androgen receptor pathway modulator and uses thereof |
| PCT/CN2017/116413 WO2018108147A1 (zh) | 2016-12-16 | 2017-12-15 | 一种组合、其应用及治疗方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3527210T3 true PL3527210T3 (pl) | 2021-11-29 |
Family
ID=62558044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17881171T PL3527210T3 (pl) | 2016-12-16 | 2017-12-15 | Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10933059B2 (pl) |
| EP (1) | EP3527210B1 (pl) |
| JP (1) | JP7048106B2 (pl) |
| KR (2) | KR102368555B1 (pl) |
| CN (1) | CN110049765B (pl) |
| AU (1) | AU2017376704B2 (pl) |
| BR (1) | BR112019010559B1 (pl) |
| CA (1) | CA3046869C (pl) |
| DK (1) | DK3527210T3 (pl) |
| ES (1) | ES2884064T3 (pl) |
| PL (1) | PL3527210T3 (pl) |
| PT (1) | PT3527210T (pl) |
| RU (1) | RU2731535C1 (pl) |
| WO (1) | WO2018108147A1 (pl) |
| ZA (1) | ZA201904328B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE530542T1 (de) | 1996-07-24 | 2011-11-15 | Celgene Corp | Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| RS52274B2 (sr) | 2005-05-13 | 2018-05-31 | Univ California | Jedinjenje diarilhidantoina |
| HUE026827T2 (en) | 2006-09-26 | 2016-07-28 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| AR065810A1 (es) | 2007-03-20 | 2009-07-01 | Celgene Corp | Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa. |
| US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| BRPI0915267A2 (pt) | 2008-11-14 | 2015-08-18 | Concert Pharmaceuticals Inc | Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição |
| PT3202460T (pt) | 2010-02-11 | 2019-08-05 | Celgene Corp | Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
| DK2877599T3 (da) | 2012-07-27 | 2020-01-20 | Aragon Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til bestemmelse af resistens overfor androgenreceptorterapi |
| JP2015531776A (ja) | 2012-09-04 | 2015-11-05 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
| AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| CN105358522A (zh) | 2013-05-10 | 2016-02-24 | 不列颠哥伦比亚癌症局分支机构 | 雄激素受体调节剂的酯衍生物及其使用方法 |
| PL3214081T3 (pl) * | 2014-10-30 | 2021-04-06 | Kangpu Biopharmaceuticals, Ltd. | Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie |
| CA3000547C (en) * | 2015-09-29 | 2021-03-23 | Kangpu Biopharmaceuticals, Ltd. | Pharmaceutical composition comprising benzoheterocyclic compound and androgen receptor pathway modulator for prevention or treatment of prostate cancer |
| KR102125661B1 (ko) * | 2017-02-13 | 2020-06-22 | 강푸 바이오파마슈티칼즈 리미티드 | 전립선암 치료용 조합, 약학 조성물 및 치료 방법 |
-
2017
- 2017-12-15 JP JP2019529888A patent/JP7048106B2/ja active Active
- 2017-12-15 PL PL17881171T patent/PL3527210T3/pl unknown
- 2017-12-15 DK DK17881171.7T patent/DK3527210T3/da active
- 2017-12-15 CN CN201780076085.3A patent/CN110049765B/zh active Active
- 2017-12-15 RU RU2019121794A patent/RU2731535C1/ru active
- 2017-12-15 AU AU2017376704A patent/AU2017376704B2/en active Active
- 2017-12-15 ES ES17881171T patent/ES2884064T3/es active Active
- 2017-12-15 CA CA3046869A patent/CA3046869C/en active Active
- 2017-12-15 KR KR1020197016757A patent/KR102368555B1/ko active IP Right Grant
- 2017-12-15 PT PT178811717T patent/PT3527210T/pt unknown
- 2017-12-15 BR BR112019010559-0A patent/BR112019010559B1/pt active IP Right Grant
- 2017-12-15 WO PCT/CN2017/116413 patent/WO2018108147A1/zh unknown
- 2017-12-15 KR KR1020227006155A patent/KR20220028178A/ko not_active Application Discontinuation
- 2017-12-15 US US16/468,385 patent/US10933059B2/en active Active
- 2017-12-15 EP EP17881171.7A patent/EP3527210B1/en active Active
-
2019
- 2019-06-25 ZA ZA2019/04328A patent/ZA201904328B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019010559B1 (pt) | 2024-01-30 |
| KR20220028178A (ko) | 2022-03-08 |
| DK3527210T3 (da) | 2021-08-09 |
| NZ753549A (en) | 2021-10-29 |
| KR102368555B1 (ko) | 2022-02-28 |
| CN110049765A (zh) | 2019-07-23 |
| BR112019010559A2 (pt) | 2019-12-03 |
| ES2884064T3 (es) | 2021-12-10 |
| CA3046869C (en) | 2022-05-17 |
| US10933059B2 (en) | 2021-03-02 |
| US20190328722A1 (en) | 2019-10-31 |
| AU2017376704A1 (en) | 2019-06-13 |
| KR20190097007A (ko) | 2019-08-20 |
| EP3527210A1 (en) | 2019-08-21 |
| CN110049765B (zh) | 2022-02-01 |
| JP7048106B2 (ja) | 2022-04-05 |
| AU2017376704B2 (en) | 2021-08-05 |
| JP2020510620A (ja) | 2020-04-09 |
| PT3527210T (pt) | 2021-08-11 |
| EP3527210A4 (en) | 2019-11-20 |
| CA3046869A1 (en) | 2018-06-21 |
| RU2731535C1 (ru) | 2020-09-04 |
| ZA201904328B (en) | 2020-12-23 |
| EP3527210B1 (en) | 2021-06-09 |
| WO2018108147A1 (zh) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281240B (en) | Androgen receptor modulator and uses thereof | |
| IL285318A (en) | Estrogen receptor modulators | |
| HK1247199A1 (zh) | 雌激素受體調節劑及其用途 | |
| SG11201606876RA (en) | Toll like receptor modulator compounds | |
| HK1248683A1 (zh) | 雜環雌激素受體調節劑及其用途 | |
| HK1258851A1 (zh) | 四氫萘雌激素受體調節劑及其用途 | |
| GB201717974D0 (en) | Modified receptors | |
| IL268263B (en) | Estrogen receptor modulators | |
| EP3604714C0 (en) | EXPLOSION PROTECTION SYSTEM | |
| KR102176229B9 (ko) | 밀봉재 조성물 | |
| EP3350167A4 (en) | Androgen receptor Antagonist | |
| SG11202003569QA (en) | Insect release devices | |
| GB201719837D0 (en) | Seal protection mechanism | |
| HUE061436T2 (hu) | Új analógok mint androgén receptor és glükokortikoid receptor modulátorok | |
| PL3527210T3 (pl) | Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania | |
| EP3568203C0 (en) | COMPOUNDS AND COMPOSITIONS | |
| EP3135669A4 (en) | Oxazolidine-based compound and selective androgen receptor agonist comprising same | |
| HUE048374T2 (hu) | Permetezhetõ fájdalomcsillapító készítmények | |
| GB201616065D0 (en) | Receptor modulator compounds | |
| GB201616071D0 (en) | Receptor modulator compounds | |
| GB201616072D0 (en) | Receptor modulator compounds | |
| GB201711319D0 (en) | Autotrip anchor release | |
| GB201710931D0 (en) | Package | |
| GB201700366D0 (en) | Combination structure for a labyrinth |